Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 15/20 | 0.57 |
| ▸ | NPY1R | P25929 | 9/20 | 0.57 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.57 |
| ▸ | NPY2R | P49146 | 5/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29461981 | 0.91 | NPY4R (0.66) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL7203848 | 0.91 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2ROPRM1 | |
| SCHEMBL31680261 | 0.90 | NPY4R (0.66) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL14450436 | 0.88 | NPY4R (0.52) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30668292 | 0.87 | OPRM1 (0.55) | NPY4RNPY1RNPY5RNPY2ROPRM1 | |
| SCHEMBL7207013 | 0.87 | OPRD1 (0.49) | NPY4RNPY1RNPY5RNPY2ROPRM1 | |
| SCHEMBL31256983 | 0.84 | NPY4R (0.55) | NPY4RNPY1RNPY5RNPY2ROPRM1 | |
| SCHEMBL32685406 | 0.83 | NPY4R (0.60) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30787055 | 0.83 | NPY4R (0.60) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29476428 | 0.83 | NPY4R (0.60) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070172422-A1 | Exponential pattern recognition based cellular targeting compositions, methods and anticancer applications | GLAZIER ARNOLD | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070172422-A1 | Exponential pattern recognition based cellular targeting compositions, methods and anticancer applications | EPHA2, EEA1, HAVCR2 | NPY4R 4332/4885NPY1R 4277/4885NPY5R 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.